{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:40Z","timestamp":1782510400768,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.014","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:17:29Z","timestamp":1777288649000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management"],"prefix":"10.1016","volume":"53","author":[{"given":"Paige","family":"Hargis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Wiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.03.014_bib1","first-page":"10","article-title":"Global burden of bladder cancer: epidemiology and trends","volume":"10","author":"Zhang","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.014_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and CIS)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.014_bib3","first-page":"287","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2023","volume":"73","author":"Patel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.014_bib4","first-page":"513","article-title":"Management of BCG-unresponsive NMIBC: recommendations from the International Bladder Cancer Group","volume":"18","author":"Witjes","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.014_bib5","first-page":"617","article-title":"Defining and treating the spectrum of BCG-unresponsive NMIBC","volume":"15","author":"Kamat","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.014_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-Unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.014_bib7","first-page":"625","article-title":"Intravesical nogapendekin alfa inbakicept (N-803) plus BCG in BCG-unresponsive NMIBC: QUILT-3.032 trial","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ucl.2026.03.014_bib8","first-page":"2045","article-title":"Cretostimogene grenadenorepvec (CG0070) for BCG-unresponsive non\u2013muscle-invasive bladder cancer: results from the phase III BOND-003 trial","volume":"42","author":"Chamie","year":"2024","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ucl.2026.03.014_bib9","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus calmette-gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2026.03.014_bib10","first-page":"1821","article-title":"TAR-200 intravesical drug delivery system with or without cetrelimab in BCG-unresponsive NMIBC: SunRISe-1 study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.014_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/iovs.64.7.10","article-title":"In vitro testing of the virus-like drug conjugate belzupacap sarotalocan (AU-011) on uveal melanoma suggests BAP1-Related immunostimulatory capacity","volume":"64","author":"Ma","year":"2023","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.014_bib12","first-page":"742","article-title":"Phase I trial of belzupacap sarotalocan (AU-011), a virus-like drug conjugate, in solid tumors","volume":"29","author":"Algazi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.014_bib13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Intravesical sequential gemcitabine and docetaxel for recurrent non\u2013muscle-invasive bladder cancer after BCG therapy","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.014_bib14","first-page":"721","article-title":"Long-term outcomes of intravesical gemcitabine and docetaxel for non\u2013muscle-invasive bladder cancer","volume":"208","author":"Steinberg","year":"2022","journal-title":"J Urol"},{"issue":"0923\u20137534","key":"10.1016\/j.ucl.2026.03.014_bib15","article-title":"1974P A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder","volume":"35","author":"DeCastro","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.014_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non\u2013muscle-invasive bladder cancer: a phase III trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.014_bib17","first-page":"412","article-title":"KEYNOTE-057: phase II trial of pembrolizumab for BCG-unresponsive non\u2013muscle-invasive bladder cancer","volume":"38","author":"Kamat","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.014_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus calmette-gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.014_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.014_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2025.43.5_suppl.667","article-title":"A phase 1\/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER cohort 4)","volume":"43","author":"Hahn","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:57:11Z","timestamp":1782507431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000406"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.014","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}